Effects of 2 mg Chlormadinone Acetate/0.03 mg Ethinylestradiol in Primary Dysmenorrhoea: The BEDY (Belara(R) Evaluation on Dysmenorrhea) Study - an Open Non-Comparative, Non-Interventional Observational Study with 4,842 Women

Schramm GAK, Waldmann-Rex S

J. Reproduktionsmed. Endokrinol 2010; 7 (Sonderheft 1), 112-118

www.kup.at/repromedizin
Online-Datenbank mit Autoren- und Stichwortsuche

Indexed in EMBASE/Excerpta Medica/Scopus
Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz
9. DVR-Kongress
Virtuellt | 1.10. – 2.10.2021

Dachverband Reproduktionsbiologie und -medizin e.V.
Back to Basics

Tagungspräsident*innen:
Prof. Dr. med. Jean-Pierre Allam, Bonn
PD Dr. rer. nat. Verena Nordhoff, Münster
Prof. Dr. med. Nicole Sänger, Bonn

Gesellschaften und Verbände:
AAD, ADE, AGRBM, BRZ, DDG, DGA, DGGEF, DGE, DGRM, DGSMTW, DIR, FertiPROTEKT, SRBM, SEF

www.dvr-kongress.de
Effects of 2 mg Chlormadinone Acetate/0.03 mg Ethinylestradiol in Primary Dysmenorrhoea: The BEDY (Belara® Evaluation on Dysmenorrhea) Study – an Open, Non-Comparative, Non-Interventional Observational Study with 4,842 Women

G. A. K. Schramm, S. Waldmann-Rex

Background: This prospective, non-interventional, observational study designed to reflect the daily medical practice which is very important for the product observation liability, was conducted according to the German Drug Law [19]. The aim of this observational non-interventional study, important for the medical practice which is very important for the medical practice which is very important for the product observation liability, was to shed further light on the significance of dysmenorrhoea and other symptoms during the administration of 2 mg CMA/0.03 mg EE in daily practice. We also present data from a large group of women on the use of analgesics and absence from school or work due to dysmenorrhoea.

Materials and Methods

Study Subjects and Design

This prospective, observational, non-interventional study – BEDY (Belara® Evaluation on Dysmenorrhea) – was conducted according to the German Drug Law and quality standards issued by the German Health Authority and was of non-interventional design to reflect daily medical practice which is very important for the product observation liability. Prescription of 2 mg CMA/0.3 mg EE was at the discretionary clinical judgement of the treating gynaecologist, with exclusion criteria limited to the licensed contraindications as stated in the prescribing information for Belara. The single patient inclusion criterion was the wish for contraception. Furthermore,
gynaecologists were asked to preferentially enroll women who complained of dysmenorrhea. All participating investigators observed and documented the intake of 2.0 mg CMA/0.03 mg EE during a 6-month period, which took place between August 2003 and November 2004. Two investigations were carried out and documented: one at baseline and the other at the end of the 6-month observation period. Beyond the conventional cycle of CMA/EE-intake (21 days of pill intake, followed by a 7-day pill-free interval), an extended-cycle regimen was also documented (2–6 blister strips, followed by a 7-day pill-free interval).

During this study, we collected data from 4,824 patients who were enrolled by 608 office-based gynaecologists throughout Germany.

**Efficacy and Tolerability Evaluation**

Demographic and morphometric data were documented at baseline, along with age, weight, risk factors for the administration of hormonal preparations and the reasons for starting or switching to CMA/EE. Primary endpoints were the incidence and intensity of dysmenorrhea, use of analgesics and absence from school or work. All efficacy parameters (cycle stability, bleeding intensity, premenstrual syndrome, mood swings, breast tenderness, headache and skin and hair condition) were defined as customary used in non-interventional studies according the established doctrine [20]. It should be noted that subjective statements of the young women and/or subjective statements of the doctor were made and, because this is a non-interventional trial no results of clinical assessment are available.

Documentation of symptoms referred to the previous 3 months before the baseline visit and to the last 4 weeks before the final visit, as reported by the subjective patient statement. Further parameters included tolerability of CMA/EE and contraceptive efficacy (Pearl index). Adverse drug reactions were recorded using coding from the Medical Dictionary for Regulatory Activities (version 10.0).

**Statistical Analysis**

Data validation and descriptive statistical analysis were performed using SPSS for Windows (release 11.0.1). We calculated descriptive p-values for changes during the observation period using the Wilcoxon signed-rank test and McNemar’s test. These were applied to distribution variables such as cycle stability, dysmenorrhea and other cycle-related parameters. Metric results were described by mean average value, standard deviation (SD), median and first, 25th, 75th and 99th percentiles. Differences in sample sizes represent missing data. The following formula served for evaluating contraceptive efficacy: Pearl index = (number of pregnancies × 1,300)/(number of cycle equivalents at 28 days).

File analysis was performed by the data-management programme DMSys (release 5.0). Validation methods were used to improve the quality of data (e.g., date specification, consistency checks, simultaneous plausibility testing and extreme-value checking). Retrospectively collected data were excluded from all efficacy analyses and used only for the tolerability assessment.

**Results**

**Baseline Characteristics**

A total of 4,824 girls and women participated in this non-interventional study (safety population). A total of 310 patients were excluded from the efficacy evaluation (efficacy population, n = 4,514) because only retrospective data were available, but were included in the safety analysis. The efficacy population comprised 25,166 treatment cycles and 1,936 woman-years. The safety population comprised 26,945.50 treatment cycles and 2,073 woman-years.

**Age, Occupation and Risk Factors**

The median age of the efficacy population was 20.9 years. More than two-thirds of women (n = 3,082; 68.3 %) were aged ≤ 24 years and 8.5 % (n = 384 were aged > 34 years (Fig. 1). The youngest patient was 13 years, while the oldest was 51 years.

According to age distribution, 2,571 patients (57.0 %) were students or in professional training. The remaining women reported being employed (n = 1,394; 30.9 %) or housewives (n = 479; 10.6 %). For 70 women (1.6 %), another occupation was stated or details were missing.

Pre-existing risk factors for OC administration included smoking (1,478 patients; 32.7 %), a positive family history of thromboembolic disease (86 patients; 1.9 %), being overweight with a body mass index of > 25 kg/m2 (712 patients; 15.8 %) or other (e.g., varicosis, hypertension, diabetes or migraine, 53 patients; 1.2 %).

**Previous Contraception and Reasons for Administration of CMA/EE**

At study entry, 2,914 participants (64.6 %) were taking an OC for the first time or had used hormonal contraception > 3 months ago (“OC starters”); 1,170 patients (25.9 %) were switching from another OC preparation to CMA/EE (“OC switchers”). No details were avail-
able for 430 participants (9.5%). In the subgroup of OC switchers, 44.8%, 19.2% and 10.3% of participants had previously taken an OC with a second-generation progestogen, a third-generation progestogen or dienogest, respectively.

The most frequently reported reasons for prescribing CMA/EE were for contraception (2,799 patients; 62.0%), to improve dysmenorrhea (2,995 patients; 66.3%) and to reduce skin or hair problems (2,150 patients; 47.6%). The percentage of patients who gave dysmenorrhea as a reason for starting CMA/EE was nearly identical in both the starter and switcher groups (68.5% and 66.0%, respectively).

The observation period on CMA/EE treatment averaged 6.01 months. Tablets were usually administered for 21 days, followed by a 7-day pill-free interval (n = 4,263; 94.4%). A minority of patients (n = 180; 4.0%) used CMA/EE in an extended-cycle regimen, with the onset of a pill-free interval most commonly after three blister strips (n = 102; 56.7%).

Contraceptive Efficacy

A total of six pregnancies occurred during 26,945.50 treatment cycles (the safety population). This resulted in an unadjusted Pearl index of 0.289 (95% confidence interval [CI]: 0.11–0.63). However, all of the pregnant women admitted CMA/EE administration irregularities.

Dysmenorrhea

Incidence and Intensity of Symptoms

The intensity and incidence of dysmenorrhea was documented as a primary endpoint of this non-interventional study. A total of 3,089 patients (78.6%) suffered from menstrual pain during the last 3 months prior to study entry. After 6 cycles/blister packs of CMA/EE treatment, only 1,531 participants reported such pain (39.0%; change vs. baseline, p ≤ 0.001). In OC switchers, the incidence of symptoms was reduced from 75.3% (n = 756) at baseline to 38.7% (n = 388) at final visit (p ≤ 0.001). The number of patients (starters and switchers) who self-reported moderate to severe symptoms decreased from 2,402 women (62.2%) at study entry to 248 women (6.4%) following 6 cycles/blister packs of CMA/EE (Fig. 2).

Administration of Analgesics

Patients suffering from moderate to severe dysmenorrhea require medication. Treatment is usually with NSAIDs and minor analgesics, based on studies that have implicated prostaglandins in the pathogenesis of dysmenorrhea [15]. In the present study, relief from pain due to CMA/EE intake was accompanied by a significant reduction in analgesic treatment.

The use of analgesics due to dysmenorrhea during the last 3 months before study entry was documented in 2,211 cases (57.3%). From these, 902 patients (23.4%) reported taking NSAIDs or other analgesics at every menstruation. After 6 cycles/blister packs of CMA/EE treatment, the percentage of women who needed analgesics decreased to 14.5% (n = 561). Only 39 women (1.0%) still stated they took analgesics frequently or at every menstruation (Fig. 3). Conversely, the number of patients who did not require pain medication grew from 1,649 (42.7%) at baseline to 3,299 (85.5%) at the final visit (change vs. baseline, p ≤ 0.001).

Absenteeism from School or Work

Dysmenorrhea interferes with daily living and is a common reason for absence from school or work. Before study entry, 1,079 participants (29.0%) disclosed absenteeism from school or work due to menstrual pain occasionally or during every menses. This number was reduced to 87 patients (2.3%) after 6 cycles/blis-
Effects of CMA/EE in Primary Dysmenorrhoea

J Reproduktionsmed Endokrinol 2010; 7 (Special Issue 1)

115

ter packs of CMA/EE treatment (change vs. baseline, \( p \leq 0.001 \)) (Fig. 4).

According our experiences with Belara® we found benefits for women with bleeding disorders, skin and hair problems and other cycle related disorders. As usual in non-interventional studies, subjective statements were made by the participants and/or their doctors. Because this was a non-interventional trial, no clinical assessment results are available.

Cycle Stability

- CMA/EE treatment reduced the number of patients who complained of intermenstrual bleeding by approximately half, from 1,232 (32.0 %) at baseline to 585 (15.2 %) after 6 cycles/blister packs (change vs. baseline, \( p \leq 0.001 \)).
- On CMA/EE administration, very severe withdrawal bleeding intensity was reported by only 36 patients (0.9 %), with participants who experienced slight to moderate menstruation increasing from 74.0 % (\( n = 2,836 \)) to 99.1 % (\( n = 3,797 \); change vs. baseline; \( p \leq 0.001 \)).
- The number of patients with Amenorrhoea (846 study participants (22.1 %) at baseline) decreased to 265 (6.9 %) patients during CMA/EE intake (change vs. baseline; \( p \leq 0.001 \)).

Skin and Hair Problems

Skin and hair problems decreased during CMA/EE intake. At the end of the 6 cycles/blister packs, the number of affected women declined by half to 1,339 (33.9 %) for skin problems and by more than half to 991 (25.2 %) for greasy hair (change vs. baseline for both; \( p \leq 0.001 \)) (Fig. 5).

Other Cycle-Related Disorders

Other cycle-related disorders investigated in this study (premenstrual syndrome, mood swings, breast tenderness, headache) decreased statistically significant decrease in number and intensity at the final visit following CMA/EE treatment (\( p \leq 0.001 \)) (Fig. 6).

Tolerability

In the safety population (\( n = 4,824 \)), 284 adverse drug reactions were documented in 223 patients (4.6 %). These reactions most commonly concerned the reproductive system and breast disorders.

Figure 4: Absence from school or work due to dysmenorrhoea, before and after the administration of 2 mg chloromadinone acetate/0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown (\( n = 3722 \)).

Figure 5: Incidence and intensity of skin and hair symptoms, before and after the administration of 2 mg chloromadinone acetate/0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown (\( n = 3951 \), Acne Prone Skin; \( n = 3934 \), Greasy Hair).

Figure 6: Incidence of moderate to severe symptoms in other cycle-related disorders, before and after the administration of 2 mg chloromadinone acetate/0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown.


**Table 1: Gynecologists’ assessment of CMA/EE treatment after 6 cycles/blisters.**

<table>
<thead>
<tr>
<th>Effects on</th>
<th>CMA/EE effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysmenorrhea</td>
<td>Very good</td>
</tr>
<tr>
<td>(n = 4514)</td>
<td>(n = 2963)</td>
</tr>
<tr>
<td>Skin/hair condition</td>
<td>54.7 %</td>
</tr>
<tr>
<td>(n = 4514)</td>
<td>(n = 2469)</td>
</tr>
<tr>
<td>Overall assessment *</td>
<td>54.5 %</td>
</tr>
<tr>
<td>(n = 1887)</td>
<td>(n = 1029)</td>
</tr>
</tbody>
</table>

*compared to the last contraceptive: subgroup of OC switchers.

(e.g., metrorrhagia, breast pain). None of the adverse drug reactions was serious.

There were no relevant weight changes during the observation period in the efficacy population. Median body weight increased slightly from 61.0 kg at baseline (n = 4,472) to 62.0 kg at final visit (n = 4,139).

**General Assessment of Therapeutic Effects**

At the end of the study, both investigators and patients assessed the therapeutic effects of CMA/EE treatment with regard to dysmenorrhea and skin or hair condition. Subjective statements were made by the participants and/or their doctors. Because this was a non-interventional trial, no clinical assessment results are available.

OC switchers also gave an overall evaluation compared to their last contraceptive. Results of the physicians’ evaluations are shown in Table 1. For the first 2 items, > 90 % of all gynaecologists judged the efficacy of CMA/EE to be “very good” or “good”. In almost 88 %, these categories were also chosen for the overall assessment in OC switchers. The patients’ assessment of therapeutic effects revealed comparable results.

The data from pill starters and pill switchers were not analysed separately in this non-interventional study and the authors acknowledge that the different pill formulations previously taken by subjects may impart a bias on the results which, in turn, limits the conclusions.

**Discussion**

The aim of this prospective, non-interventional study was to examine the influence of CMA/EE on cycle-related disorders and dermatological problems, with a main focus on primary dysmenorrhea in daily practice. Analysis of the present data confirms that CMA/EE provides reliable contraceptive efficacy and good tolerability. Incidences of adverse drug reactions were low (4.6 %) and in line with the known tolerability profile of OC treatment. Previous findings have highlighted several non-contraceptive benefits for the CMA-containing OC, such as anti-androgenic properties, sustained cycle stability, substantial relief of dysmenorrhea and improvement of well-being [12–18]. The present non-interventional study supports those results. The effects were particularly pronounced for symptoms of moderate to severe intensity.

**CMA/EE Treatment Provides Substantial Relief of Dysmenorrhea**

Primary dysmenorrhea usually begins in adolescence after the establishment of ovulatory cycles [21, 22]. The incidence is between 43 and 91 % [9].

Age is a determinant of menstrual pain, with symptoms being more pronounced in adolescents than in older women [1, 7, 23]. Accordingly, the present study encompassed a relatively young population with an average age of 21 years. Gynaecologists were specifically instructed to focus on dysmenorrhea for inclusion in this study. This resulted in a study population in which almost eight out of 10 participants (78.6 %) suffered from painful menstruation at study entry.

CMA/EE administration substantially reduced the intensity and incidence of dysmenorrhea symptoms. This was shown for both OC starters and OC switchers, indicating a pronounced effect of the gestagen component CMA on dysmenorrhea. Women with no contraindications who suffer from painful menstruation should be offered NSAIDs as a first-line treatment for pain relief. NSAIDs were found to be an effective treatment for dysmenorrhea in a review of 63 randomized controlled trials, although overall adverse effects were significantly more common with NSAIDs compared to placebo (odds ratio 1.52, 95%-CI: 1.09–2.12) [10]. Adverse effects include gastrointestinal intolerance, headaches and drowsiness [6]. In the present study, 57.3 % of patients used analgesics for their dysmenorrhea. This fraction was reduced to 14.5 % during CMA/EE intake. The distinct menstrual pain reduction also resulted in a dramatic decline in current school or job absenteeism – a common problem for many adolescent and young women with dysmenorrhea.

Although several mechanisms for the dysmenorrhea pain relief attained with OC have been suggested, suppression of prostaglandin synthesis, leading to reduced uterine contractions, represents one of the most probable pathways [9]. Beyond this pathophysiological background, multiple other factors may also play a role in the perception and severity of pain [6].

Current evidence suggests that the pathogenesis of primary dysmenorrhea is due to the action of prostaglandin F, a potent myometrial stimulant and vasoconstrictor, in the secretory endometrium [24]. Elevated prostaglandin levels have been found in the endometrial fluid of women with dysmenorrhea, and correlated well with the degree of pain [25]. A 3-fold increase in endometrial prostaglandins occurs from the follicular to the luteal phase of the menstrual cycle, with a further increase during menstruation [26]. Progesterone inhibits prostaglandin synthesis and has a relaxing influence on the myometrium via the α-adrenergic receptor. The fall in progesterone in the late luteal phase results in increased prostaglandins in the endometrium, followed by rising myometrial tone and excessive uterine contraction [27, 28].

CMA (17α-acetoxy-6-chloro-4,6-pregnadiene-3,20-dione) has a similar structure to progesterone and a strong pro-
gestogenic effect – about one-third higher than that of naturally produced progesterone [29]. The high intrinsic activity of CMA at progesterone receptors and possible further pharmacological effects may provide a rationale for its marked beneficial effects on dysmenorrhea in women of reproductive age [30].

The data from OC starters and OC switchers were not analysed separately in this study. We acknowledge that the different OC formulations previously taken by subjects may impart a bias on the results. This, in turn, limits the conclusions.

Conclusions

The results of this 6-month prospective study provide strong evidence for a substantial improvement in dysmenorrhea and related problems following the administration of 2 mg CMA/0.03 mg EE. The high efficacy in terms of menstrual pain reduction may be due to the distinct progestogenic effect of CMA, a derivative of naturally produced progesterone.

Furthermore, this study supports earlier findings that CMA/EE offers reliable contraceptive efficacy and an excellent tolerability profile, and produces major benefits on bleeding intensity, cycle stability and skin or hair problems.

Acknowledgement

The study was conducted and sponsored by Grünenthal GmbH, Germany. The authors would like to thank all of the 608 participating investigators for their contributions and ZaicomMMC for their editorial support.

References:

Mitteilungen aus der Redaktion

Besuchen Sie unsere Rubrik

☑ Medizintechnik-Produkte

Neues CRT-D Implantat
Intica 7 HFT OP von Biotronik

Aspirator 3
Labotect GmbH

Artis pheno
Siemens Healthcare Diagnostics GmbH

Philips Azurion:
Innovative Bildgebungslösung

InControl 1050
Labotect GmbH

e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.
Die Lieferung umfasst 4-5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☑ Bestellung e-Journal-Abo

Haftungsausschluss


Bitte beachten Sie auch diese Seiten:

Impressum
Disclaimers & Copyright
Datenschutzerklärung